Biocon Biologics’ commercial footprint for biosimilars straddles the developed and developing countries by leveraging strong regional and global partnerships. Biocon Biologics’ products are marketed globally through a hybrid commercial model, wherein the company has direct commercial presence in a few countries and in others, the company leverages the commercial strengths of its partners.
The proposed acquisition of Viatris’ global biosimilars business will allow Biocon Biologics to have a direct commercial presence in the advanced markets of U.S., Canada, EU, Australia and New Zealand, in addition to several emerging markets.
In emerging markets, Biocon Biologics makes its biosimilars available to patients through partnerships with leading local pharmaceutical players. This organically developed B2B business has increased its breadth by entering new countries through regional partnerships and addition of new products following approval in developed markets.